This is to inform you that the Board of Directors in its meeting held on has approved and granted in-principal approval for providing corporate guarantee as per the disclosure annexed herewith.
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nephrocare Health Services Limited held its Board meeting on May 19, 2026 and approved multiple items. The company reported standalone revenue of Rs. 6,297.43 Crore for FY26, up 16% from Rs. 5,435.97 Crore in FY25. However, the company swung to a loss before tax of Rs. 37.69 Crore compared to a profit of Rs. 453.60 Crore in FY25. Finance costs increased sharply to Rs. 497.61 Crore from Rs. 142.99 Crore due to non-cash FVTPL interest expenses. The Board approved investment of up to Rs. 10 Crore in its Nepal subsidiary and granted in-principal approval for providing collateral/security support of Rs. 70 Crore each for its Singapore and Saudi Arabia subsidiaries to help them avail credit facilities from overseas banks. The company also re-appointed BDO India LLP as internal auditor for FY26-27.
The transition from profit to loss is concerning, though partly due to non-cash finance costs related to IPO-related instruments. The Rs. 140 Crore in corporate guarantees for overseas subsidiaries increases contingent liability exposure. However, the IPO proceeds have significantly strengthened the balance sheet with cash balances increasing from Rs. 38.54 Crore to Rs. 936.78 Crore.